Allegis Investment Advisors’s Myriad Genetics MYGN Stock Holding History

Allegis Investment Advisors’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-655	Closed	-$28K	–	657
2015 Q4	$28K	Buy	+655	New	+$27.7K	0.02%	431

Other funds holding MYGN

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

IAM

Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RIM

RS Investment Management San Francisco, California $9.73B AUM 3.24% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

Allegis Investment Advisors's MYGN Position: Q1 2016 in Review

Allegis Investment Advisors sold out of Myriad Genetics (MYGN) in Q1 2016, closing a stake of 655 shares — an estimated $28K sold.

Allegis Investment Advisors first reported a position in MYGN in Q4 2015 and held it in 1 quarter. The position peaked at $28K in Q4 2015. 233 funds tracked by Wall St. Rank hold MYGN as of Q1 2016.

Allegis Investment Advisors reported no remaining Myriad Genetics position as of Q1 2016 after selling out during the quarter.
Allegis Investment Advisors sold 655 Myriad Genetics shares in Q1 2016, an estimated $28K.
Allegis Investment Advisors first reported a position in Myriad Genetics in Q4 2015 and held it in 1 quarter.
Allegis Investment Advisors's Myriad Genetics position peaked at $28K in Q4 2015.
233 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2016.

Based on Allegis Investment Advisors's 13F filing for Q1 2016, filed 9 May 2016.